Taurus Introduces Patented Liposomal Delivery System for Prescription Medications, Advancing a New Era in Drug Delivery
The patented StatRX ampoule used by Taurus
Innovative delivery method enhances absorption, convenience, and patient experience across multiple therapies
SAN DIEGO, CA, UNITED STATES, March 18, 2026 /EINPresswire.com/ -- Taurus, a pioneering healthcare company, today announced the launch of its patented liquid liposomal delivery system for prescription medications, a first-of-its-kind platform designed to improve how medications are absorbed, administered, and experienced by patients.
The platform utilizes advanced liposomal technology, enabling active ingredients to be encapsulated for improved bioavailability compared to traditional oral dosage forms. Taurus’ approach allows multiple active ingredients to be combined into a single liquid formulation, creating a more efficient and patient-friendly treatment experience.
“Healthcare has long relied on outdated delivery methods that don’t fully optimize how medications are absorbed or experienced,” said Elias, CEO of Taurus. “Our patented liposomal platform represents a fundamental shift—enabling more effective delivery, simplified regimens, and a better overall experience for patients and providers.”
A Platform Approach to Prescription Medications:
Traditional medications are often limited by inconsistent absorption, delayed onset, and complex dosing regimens. Taurus’ liposomal delivery system addresses these challenges by:
Enhancing bioavailability through advanced liposomal encapsulation
Enabling multi-compound formulations within a single prescription
Providing a liquid format designed for ease of administration
Reducing treatment complexity, minimizing the need for multiple medications
This platform approach is designed to improve adherence while unlocking new possibilities for how prescription therapies are formulated and delivered.
Medications utilizing this delivery system are available by prescription only and should be used under the supervision of a licensed healthcare provider.
Initial Application in Men’s Health
Taurus has begun deploying its liposomal platform in men’s health, including the development of a 4-in-1 liquid medication formulations. This initial application demonstrates the platform’s ability to combine multiple active ingredients into a single, optimized delivery system.
The company plans to expand the platform across additional therapeutic areas, leveraging its flexibility to support a wide range of prescription treatments.
Designed for Modern, Accessible Care
The platform is built to integrate seamlessly with telehealth and digital care models, aligning with the growing demand for more accessible and patient-centric healthcare solutions.
“Patients today expect healthcare to be as efficient and personalized as the rest of their lives,” added Elias, CEO “This platform enables that shift by combining advanced science with a modern delivery experience.”
Elias Ghosn
Taurus Medical, Inc
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
